Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Time to onset of action of tolterodine in spinal cord injury patients with neurogenic detrusor overactivity
2004-002640-97Phase 4Completed
- Sponsor
- Pfizer
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in detrusor hyperreflexia (DH) comparing Tolterodine 2 mg with Placebo (2 arms). Primary endpoint: Area under the pressure curve of the provoked detrusor contraction. Started Oct 2004; status: completed.
02
Drugs
tolterodine
03
Conditions
detrusor hyperreflexia (DH)
Beyond the preview
Go deeper on 2004-002640-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002640-97.